In order to accelerate innovation and upgrading, this pharmaceutical company has successively introduced a number of innovative drugs

Recently, Huadong Medicine issued an announcement stating that Sinclair, a wholly-owned subsidiary of the company's medical aesthetics, has signed an exclusive license agreement with KiOmed Pharma SA of Belgium, and will obtain its 4 chitosan medical aesthetics products under research and all chitosan related products that will be developed subsequently.
Exclusive license in the field of dermatology and beauty in other regions of the world except the United States
.
At that time, Sinclair will pay KiOmed an advance payment of 4 million euros, as well as a R&D registration milestone payment of no more than 10 million euros, and an agreed percentage of net sales commission fees
.
It is worth mentioning that public information shows that the transaction party KiOmed is a company that can produce high-purity natural (non-animal origin) medical-grade chitosan extracted from edible fungi at the cGMP level in an ISO13485 certified factory
.
Therefore, the industry believes that the cooperation between Huadong Medicine and KiOmed will further enrich its medical beauty filling product pipeline and achieve full product coverage in the fields of hyaluronic acid, collagen stimulants, and skin kinetics
.
It should be noted that, in addition to accelerating the deployment of new products in the field of medical beauty, Huadong Medicine has also made new moves in the field of hypoglycemia
.
It is reported that on October 6, it reached a strategic cooperation with Takeda on the commercialization of type 2 diabetes drug Nisina in China
.
It is reported that the alogliptin benzoate tablets in this transaction are dipeptidyl peptidase-4 (DPP-4) inhibitors for the treatment of type 2 diabetes, and have been approved by Japan PDMA, US FDA, and EU EMA
.
According to Takeda's annual report, from April 1, 2020 to March 31, 2021, sales of alogliptin benzoate tablets were 57.
7 billion yen (approximately 3.
393 billion yuan)
.
In addition, data shows that the domestic sales of alogliptin benzoate tablets in 2020 is about 150 million yuan, a year-on-year increase of 61.
38%
.
Of course, in addition, Huadong Medicine also has a number of diabetes products that have also been deployed
.
It is reported that Huadong Medicine currently has more than 20 commercialized and researched products, covering a-glycosidase inhibitors, DPP-4 inhibitors, SGLT-2i, GLP-1R agonists, and GLP-1R and GIPR dual agonists , Insulin and its analogs, and many other mainstream clinical targets, basically covering the current mainstream hypoglycemic products
.
In fact, as early as 2018, Huadong Medicine began to implement the second major transformation.
In the same year, Huadong Medicine established joint scientific research offices in Boston and Silicon Valley, and publicly stated that it would continue to increase R&D investment and accelerate the development of innovative drugs.
R&D and external introduction efforts, and strive to introduce 1-2 overseas new drug varieties every year
.
From the current point of view, through intensive license in, Huadong Medicine is continuously accelerating innovation and upgrading, and continuously improving research and development capabilities
.
However, although the license in model is a convenient way to expand the product pipeline, the industry has also pointed out that pharmaceutical companies cannot rely on this model for a long time, and only companies with continuous R&D and innovation capabilities will be recognized by the capital market
.
In this regard, Huadong Medicine obviously feels the same.
In recent years, it can be clearly seen that while Huadong Medicine innovation focuses on external introduction and cooperation, it is also constantly developing its own research and development
.